Thinning bone and inhaled corticosteroid in COPD: what to do until there is definitive proof?
Man
S F Paul
SFP
Department of Medicine, Respiratory Division, University of British Columbia, and the Heart and Lung Institute, St. Paul's Hospital, Vancouver, BC, Canada. Electronic address: pman@providencehealth.bc.ca.
Sin
Don D
DD
Department of Medicine, Respiratory Division, University of British Columbia, and the Heart and Lung Institute, St. Paul's Hospital, Vancouver, BC, Canada.
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D004164:Diphosphonates / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000453:epidemiology; D015995:Prevalence; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D004164:Diphosphonates